Skip to main content

Table 1 Comparison of the baseline characteristics and pathological outcomes between the AYA and non-AYA groups

From: Outcomes of adolescent and young patients with hepatocellular carcinoma after curative liver resection: a retrospective study

Characteristics AYA group (n = 73) Non-AYA group (n = 170) P value
Age (years) 36.0 ± 4.4 62.0 ± 6.4 < 0.01
Sex, n (%)
 Male 56 (76.7%) 140 (82.4%)  
 Female 17 (23.3%) 30 (17.6) NS
Etiology, n (%)
 HBV 60 (82.1%) 141 (83.0%)  
 Others 13 (17.8%) 29 (17.0%) NS
BMI (kg/m2) 22.1 ± 1.2 20.6 ± 0.9 NS
AST (U/L) 42 (23–119) 50 (16–269) NS
ALT (U/L) 62 (22–167) 54 (9–204) NS
Albumin (g/dL) 4.2 ± 0.4 4.0 ± 0.5 NS
Total bilirubin (mg/dL) 0.7 ± 0.4 0.7 ± 0.4 NS
Platelet (× 103/mm3) 199 (40–362) 183 (66–393) NS
INR 1.1 ± 0.1 1.1 ± 0.1 NS
AFP (ng/dL) 5923 (2–59,403) 3341 (1–59,779) < 0.01
PIVKA-II 271 (10–500) 238 (11–500) NS
ICG R15 (%) 8.5 (2.4–41.5) 10.0 (3.7–48.6) NS
Child-Pugh grade B, n (%) 2 (3.0%) 5 (2.9%) NS
Family history of HCC or other cancers, n (%) 15 (20.5%) 20 (11.8%) < 0.05
Maximum tumor size > 5 cm 42 (57.5%) 76 (44.1) < 0.05
Multiple tumors 6 (8.2%) 15 (8.8%) NS
Microvascular invasion 64 (87.7%) 121 (71.2%) < 0.01
Portal vein invasion 24 (32.9%) 33 (19.4%) < 0.01
Satellite nodules 12 (16.4%) 31 (18.2%) NS
Edmondson grade
 I + II 36 (49.3%) 151 (88.8%)  
 III + IV 37 (50.7%) 19 (11.2%) < 0.01
Tumor capsule formation 39 (53.4%) 126 (74.1%) < 0.01
Hepatic capsule invasion 8 (11.0%) 9 (5.3%) <0.01
Microvascular tumor emboli 47 (64.4%) 119 (70.0%) NS
TNM stage
 I + II 25 (34.2%) 68 (40.4%)  
 III + IV 48 (65.8%) 102 (60.0%) NS
Resection margin < 1 cm 36 (49.3%) 77 (45.3%) NS
  1. HCC hepatocellular carcinoma, NS not significant